MedVax Technologies, Inc. to Present at Biotech Showcase™ 2015

Share Article

MedVax Technologies, Inc. CEO, Robert Brooks, will be featured speaker at Biotech Showcase™ 2015

MedVax Technologies, Inc., a mid-stage pharmaceutical company focused on the development and commercialization of cancer vaccines, today announced that Robert K. Brooks, Chief Executive Officer, will be presenting at the Biotech Showcase™ 2015 Conference being held in San Francisco, California.

Event: Biotech Showcase™ 2015 Conference
Date: Monday, January 12, 2015
Time: 2:00 pm Pacific Time

Co-produced by Demy-Colton Life Science Advisors and EBD Group, Biotech Showcase™ is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies an opportunity to present to, and meet with, investors and pharmaceutical executives during the course of one of the industry's largest annual healthcare investor conferences. Now in its seventh year, Biotech Showcase™ is expected to attract upwards of 1,500 attendees.

About MedVax Technologies, Inc.

MedVax is a biopharmaceutical company discovering and commercializing cancer vaccines. MedVax's portfolio includes: MX-402, a unique B-cell epitope HER-2 Peptide vaccine that had showed strong signals of efficacy in an interim Phase I trial, 8 of 12 patients showed clinical benefit, with one patient in complete remission; and, MX-225, an autologous P53 dendritic cell vaccine that completed two Phase IIa trials in Small Cell Lung Cancer, and recruiting in breast cancer. Medvax’s team is comprised of world renowned scientists and biotech industry professionals.

Cautionary Note on Forward-Looking Statements
This press release and any statements of representatives and partners of MedVax Technologies, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors, many of which are beyond the Company's control. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Company Contacts:
Robert K. Brooks, JD
President & Chief Executive Officer
MedVax Technologies, Inc.
25 SE 2nd Avenue, Suite 504
Miami , FL 33131
(305) 371-2301 (Office)
(305) 371-2304 (Fax)

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Candace Cobos

Candace Cobos